Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05611216 · ClinicalTrials.gov registry record
Clinical Outcomes of 3L+ Therapies Among Patients With Chronic Myeloid Leukemia and Those With T315I Mutation
A clinical trial, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- 164
- Enrollment target
NCT05611216: Completed study, sponsored by Novartis Pharmaceuticals.
NCT05611216 is a clinical trial that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 164 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05611216 has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- 164 participants
- Enrollment target
Study Summary
The study was a retrospective, non-interventional patient chart review and used a panel of oncologists/hematologists from the US to collect real-world clinical outcomes of patients with CML-CP in 3L+ and those with the T315I mutation.
Primary Outcome
To evaluate treatment patterns in patients with CML-CP who were previously treated with TKI or other CML treatments and were relapsed/refractory to/were intolerant/had other reasons for switching of CML therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 164 participants |
| Start Date | 2020-12-01 |
| Est. Completion | 2021-12-23 |
What the finished NCT05611216 record still lists
NCT05611216 is an observational study that tracks outcomes without assigning an intervention. The registered 164 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT05611216 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05611216 about?
NCT05611216 is a clinical study titled "Clinical Outcomes of 3L+ Therapies Among Patients With Chronic Myeloid Leukemia and Those With T315I Mutation". The study was a retrospective, non-interventional patient chart review and used a panel of oncologists/hematologists from the US to collect real-world clinical outcomes of patients with CML-CP in 3L+ and those with the T315I mutation.
What is the current status of trial NCT05611216?
This trial is currently completed. The enrollment target is 164 participants. The study started on 2020-12-01. Estimated completion is 2021-12-23.
Who is sponsoring clinical trial NCT05611216?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04891289 · 164 participants · Phase 2
Gemcitabine and Oxaliplatin Chemotherapy With or Without a Floxuridine and Dexamethasone Pump in People With Cholangiocarcinoma That Cannot Be Removed With Surgery
- NCT04893226 · 164 participants · NA
Time-Restricted Feeding Intervention in Metabolically-Unhealthy Postmenopausal Women
- NCT05270213 · 164 participants · Phase 1
Evaluation of RBS2418 in Subjects With Advanced, Metastatic Solid Tumors
- NCT05543681 · 164 participants · Phase 2
Clinical Trial on Agitation in Alzheimer's Dementia
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI